

# ARTIFICIAL INTELLIGENCE FOR IMPROVED PATIENT OUTCOMES

RYAN P. MOORE<sup>A</sup>, HENRY J. DOMENICO<sup>A</sup>, DANIEL W. BYRNE<sup>A</sup>, HOLLY B. ENDE<sup>B</sup>, APRIL BARNADO<sup>C,D</sup>, SHANNON WALKER<sup>E</sup>

<sup>A</sup>DEPARTMENT OF BIOSTATISTICS, VANDERBILT UNIVERSITY MEDICAL CENTER  
<sup>B</sup>DEPARTMENT OF ANESTHESIOLOGY, VANDERBILT UNIVERSITY MEDICAL CENTER  
<sup>C</sup>DEPARTMENT OF MEDICINE, VANDERBILT UNIVERSITY MEDICAL CENTER  
<sup>D</sup>DEPARTMENT OF BIOMEDICAL INFORMATICS, VANDERBILT UNIVERSITY MEDICAL CENTER  
<sup>E</sup>DEPARTMENTS OF PATHOLOGY, MICROBIOLOGY, AND IMMUNOLOGY AND PEDIATRICS

## BACKGROUND

- AI's potential in medicine is promising, but there is little rigorous evidence that it improves patient outcomes.
- Most studies lack proper outcome evaluation or have inadequate study design – the RCT is critical for proving that AI can improve patient outcomes.
- AI should assist physicians, not replace them, to improve patient care and reduce physician burnout.
- The last mile is using pragmatic RCTs to measure AI's impact on patient outcomes and then implementing models that have been proven to have an impact on patient outcomes.


## WHAT IS NOT WORKING

- Most published models are not developed in a way that can be implemented.
- Even fewer are evaluated in a way that can show AI benefits patients.
- It is not enough to develop an accurate model.
- The important question is whether the model/clinician partnership is an improvement over current standard of care.

| Study   | Operationalizable | Broadly Applicable | Updated | Actionable | Validated | Total Criteria Met |
|---|-------------------|--------------------|---------|------------|-----------|--------------------|
| Ende et al. (2022)                              | ●                 | ●                  | ●       | ●          | ●         | 5                  |
| Ahmadzai et al. (2018) <sup>1</sup>             | ●                 | ●                  | ●       | ●          | ●         | 4                  |
| Helman et al. (2015) <sup>2</sup>               | ●                 | ●                  | ●       | ●          | ●         | 4                  |
| Rubio-Akarez et al. (2018) <sup>3</sup>         | ●                 | ●                  | ●       | ●          | ●         | 3                  |
| Albright et al. (2019) <sup>4</sup>             | ●                 | ●                  | ●       | ●          | ●         | 3                  |
| Goad et al. (2021) <sup>5</sup>                 | ●                 | ●                  | ●       | ●          | ●         | 3                  |
| Koopmans et al. (2014) <sup>6</sup>             | ●                 | ●                  | ●       | ●          | ●         | 2                  |
| Coriet et al. (2015) <sup>7</sup>               | ●                 | ●                  | ●       | ●          | ●         | 2                  |
| Suta et al. (2015) <sup>8</sup>                 | ●                 | ●                  | ●       | ●          | ●         | 2                  |
| Nieprasch-von Dollen et al. (2016) <sup>9</sup> | ●                 | ●                  | ●       | ●          | ●         | 2                  |
| Kim et al. (2017) <sup>10</sup>                 | ●                 | ●                  | ●       | ●          | ●         | 2                  |
| Shinohara et al. (2018) <sup>11</sup>           | ●                 | ●                  | ●       | ●          | ●         | 2                  |
| Venkatesh et al. (2020) <sup>12</sup>           | ●                 | ●                  | ●       | ●          | ●         | 2                  |
| Liu et al. (2022) <sup>13</sup>                 | ●                 | ●                  | ●       | ●          | ●         | 2                  |
| Prata et al. (2011) <sup>14</sup>               | ●                 | ●                  | ●       | ●          | ●         | 1                  |
| Chen et al. (2011) <sup>15</sup>                | ●                 | ●                  | ●       | ●          | ●         | 1                  |
| Biguzzi et al. (2012) <sup>16</sup>             | ●                 | ●                  | ●       | ●          | ●         | 1                  |
| Yoon et al. (2014) <sup>17</sup>                | ●                 | ●                  | ●       | ●          | ●         | 1                  |
| Baba et al. (2015) <sup>18</sup>                | ●                 | ●                  | ●       | ●          | ●         | 1                  |


## MODEL BUILDING APPROACH

- Model agnosticism: use the best tool for the job. Fit multiple models and compare.
- 80/20 temporal validation split using single data pull. No 50/50 forced balancing.
- Prespecify clinically relevant predictors in the model and avoid reverse causation - automated variable selection results can result in pitfalls.
- Use bootstrapping for parameter optimization and model validation using all candidate predictors.




## MODEL IMPLEMENTATION

| VTE Risk (%) | Medication | DVT Indicator |
|--------------|------------|---------------|
| 77           |            | X             |
| 66.5         | X          |               |
| 54.5         |            |               |
| 34.5         |            |               |
| 27.7         | X          |               |
| 26.7         |            |               |
| 25.9         |            |               |
| 24.3         |            |               |
| 22.3         | X          |               |
| 22.2         |            |               |
| 21.1         |            |               |




## PRAGMATIC MODEL EVALUATION




- The RCT is critical for evaluating efficacy of the intervention – would not implement a drug without a clinical trial

- RCT evaluates clinically relevant patient-centered outcomes, not model performance.
- Before/After evaluations are prone to regression to the mean, confounding bias, and contribute to alert fatigue.
- Patient-level RCTs can be designed to fit seamlessly into workflow.
- Data from RCT allow us to see what is/is not working, improve the intervention, and gain valuable data even when trial is negative.




## AUTOIMMUNE DISEASE RISK PREDICTION

- Positive antinuclear antibodies (ANAs) cause diagnostic dilemmas.
- First-of-its-kind autoimmune disease risk model for ANA positive patients, seamlessly integrated into EHR and undergoing pragmatic RCT.
- Recommendation for expedited rheumatology consult for high-risk patients.



## POSTPARTUM HEMORRHAGE PREDICTION

- Postpartum hemorrhage the leading cause of maternal death globally
- Developed and validated modernized predictive model for PPH
- Currently undergoing evaluation at an external site and with a pragmatic RCT



## REFERENCES

- Byrne DW, Domenico HJ, Moore RP. Artificial Intelligence for Improved Patient Outcomes-The Pragmatic Randomized Controlled Trial Is the Secret Sauce. *Korean J Radiol.* 2024 Feb;25(2):123-125. doi: 10.3348/kjr.2023.1016. Epub 2024 Jan 10. PMID: 38238014; PMCID: PMC10831302.
- Artificial Intelligence for Improved Patient Outcomes: Principles for Moving Forward with Rigorous Science First Edition by Daniel W. Byrne. ISBN -10 1975197933. ISBN-13 978-1975197933. LWW; First Edition (April 6, 2023)
- Barnado A, Moore RP, Domenico HJ, Green S, Camai A, Suh A, Han B, Walker K, Anderson A, Caruth L, Katta A, McCoy AB, Byrne DW. Identifying antinuclear antibody positive individuals at risk for developing systemic autoimmune disease: development and validation of a real-time risk model. *Front Immunol.* 2024 Mar 20;15:1384229. doi: 10.3389/fimmu.2024.1384229. PMID: 38571954; PMCID: PMC10987951.
- Ende HB, Domenico HJ, Polic A, Wesoloski A, Zuckerwise LC, McCoy AB, Woytash AR, Moore RP, Byrne DW. Development and Validation of an Automated, Real-Time Predictive Model for Postpartum Hemorrhage. *Obstet Gynecol.* 2024 Jul 1;144(1):109-117. doi: 10.1097/AOG.0000000000005600. Epub 2024 May 10. PMID: 38723260.
- Walker SC, Creech CB, Domenico HJ, French B, Byrne DW, Wheeler AP. A Real-time Risk-Prediction Model for Pediatric Venous Thromboembolic Events. *Pediatrics.* 2021 Jun;147(6):e2020042325. doi: 10.1542/peds.2020-042325. Epub 2021 May 19. PMID: 34011634; PMCID: PMC8168609.
- Walker SC, French B, Moore RP, Domenico HJ, Wanderer JP, Mixon AS, Creech CB, Byrne DW, Wheeler AP. Model-Guided Decision-Making for Thromboprophylaxis and Hospital-Acquired Thromboembolic Events Among Hospitalized Children and Adolescents: The CLOT Randomized Clinical Trial. *JAMA Netw Open.* 2023 Oct 2;6(10):e2337789. doi: 10.1001/jamanetworkopen.2023.37789. PMID: 37831448; PMCID: PMC10576217.

Shiny Application



Artificial Intelligence for Improved Patient Outcomes Book

